Safety and antitumor activity of the first-in-class EGFR–HER3 bispecific antibody–drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase Ib study☆

Annals of Oncology · Elsevier

Аннотация

Publication date: November 2026 Source: Annals of Oncology, Volume 37, Issue 11 Author(s): J. Zhang, Y. Meng, Y. Du, T. Sun, J. Cui, Y. Chen, Y. Sun, Y. Wang, W. Chen, F. Xu, Y. Shi, Y. Chen, K. Wang, G. Jin, H. Zhou, Z. Zhuang, W. Xie, Z. Wang, M. Sun, Q. Wen

Читать у издателя →

Похожие статьи